Karla Viviani Allebrandt, PD Dr.

Director of Experimental Medicine Studies, leading large external collaborations, and BI cross-functional teams to design, execute and evaluate studies of biomarkers to support the TA Precision Psychiatry approach in early and late clinical trials. Working collaboratively within BI CNS TA to optimise the translational strategy, contributing to in depth review of external Innovations, and designing program-specific biomarker strategies in early clinical trials. As Digital Biomarker Strategy Lead, drove stakeholders review on digital biomarkers for the CNS TA, leading studies to explore digital endpoints relationships to clinical outcome assessments and neurophysiological markers. At Sanofi-Aventis, led strategy and data interpretation of projects focused on Target Identification, Biomarker Discovery, Patient Stratification, and Reconstruction of Molecular Mechanisms of Drug Response and Cardio-metabolic Disease. At LMU-Munich, Private Docent in Medical Psychology (at Medical Faculty) with 8 years’ experience as Principal Investigator. Focus areas: Genetic Epidemiology, circadian rhythms, and Sleep Research.